AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 141 min read$LQDA

Kaseta Michael sold $539K of LQDA

Kaseta Michael (CFO and COO) sold 18,938 shares of Liquidia Corp (LQDA) at $28.48 ($0.54M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kaseta Michael
Published Oct 14, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The disclosed sale adds new information about insider activity, offering a modest trading cue.

02

Market read

New insider sale provides a low‑actionability signal for traders monitoring LQDA.

03

What to watch

Potential upcoming clinical data releases could offset the negative signal from the sale.

Relevance 4/10Novelty 7/10Timing: after‑hours filing

Background

Form 4 filings disclose insider transactions; CFOs selling shares can influence short‑term price perception.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

CFO Kaseta Michael sold 18,938 shares for $539,354, a 10b5‑1 plan transaction disclosed on Form 4.

Expected impact

likely slight pressure as market prices in the CFO's sale.

Evidence & confidence

The sale size is modest relative to holdings but represents a direct insider divestment, which can be interpreted as a bearish signal.

Market effects

Sector

Minimal impact on biotech sector; similar insider sales are common.

Regional

No broader regional effect.

Global

Limited to investors tracking Liquidia Corp.

Counterpoint

What could challenge this read

The sale could be routine under a 10b5‑1 plan and not reflect negative outlook.

Key entities

  • Company
    Liquidia Corp

    Biotech firm listed on NASDAQ under LQDA.

  • Individual
    Kaseta Michael

    Chief Financial Officer and Chief Operating Officer of Liquidia Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

OCT 20
$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

news.alphastreet.com1 min
OCT 16
$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

biobuzz.io7 min
OCT 15
$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.

investing.com2 min